In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events
- PMID: 36063554
- DOI: 10.7326/J22-0067
In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events
Abstract
Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327:1888-98. 35579642.
Comment on
-
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368. JAMA. 2022. PMID: 35579642 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous